Venatorx Pharmaceuticals announced that it has received an investment of $8.9M from the Wellcome Trust Translation Fund for the “Development of novel small molecules for the treatment of antibiotic resistant bacterial infections.”
Venatorx is developing new antibacterial therapeutic products to address multi-drug resistant gram negative bacteria, including resistant E. coli, K. pneumoniae, and P. aeruginosa, important causative agents for complicated urinary tract infections, complicated intra-abdominal infections and many types of serious pneumonia.